What top creators are saying about Eli Lilly and Company(LLY)— Page 6

Viewed as the clear winner in the obesity drug market, with its drugs Mounjaro and Zepbound 'crushing' the competition from Novo Nordisk.

The speaker believes that any major issues for its competitor, Novo Nordisk (NVO), would also be bearish for Eli Lilly.

Strongly preferred over Novo Nordisk for exposure to the GLP-1 market due to its superior current drug (Trizepatide) and a more promising drug in its pipeline (Retatrutide).

Shares were pulled down by negative news from competitor Novo Nordisk, suggesting broader market concerns about competition in the GLP-1 drug sector.

Planning a $27 billion investment in U.S. operations, reinforcing the view that established brand-name drug makers are well-positioned to absorb onshoring costs.

The speaker is bullish due to Lilly's leadership in the high-growth GLP-1 market and its 'Lilly direct' program, which is seen as a key strategic advantage.

The company faces significant political and regulatory risk due to government-mandated price caps on insulin. This pressure has led to price slashing, which can curtail long-term profitability and is a key risk factor for investors.

The speaker's preferred pure-play investment in the GLP-1 weight-loss drug space, favored over Novo Nordisk (NVO) due to the belief that its drugs are superior.

Mentioned as a 'Big Pharma' competitor to Hims & Hers, representing a major competitive threat in the lucrative weight-loss drug market.

A major competitor to Novo Nordisk whose weight-loss drugs (Zepbound, Mounjaro) are reportedly gaining significant market share and seeing prescription numbers grow much faster.

Mentioned as a potential future partner for HIMS, which presents a strategic opportunity for HIMS to gain access to popular weight loss drugs if it ceases its compounding activities.